Glucocorticoids (GCs) play a pivotal role in carbohydrate metabolism. They counteract insulin by decreasing peripheral glucose uptake and stimulating hepatic gluconeogenesis, although they are best known for inducing insulin resistance (IR). Moreover, GCs may attenuate the incretin effect. Nevertheless, their direct impact on beta cells is not fully defined. This review aims to present the current understanding of this subject. Humans exposed to GC excess display IR, impaired glucose tolerance, and eventually develop diabetes. Although their insulin levels are elevated, they present lower insulin output in response to glucose than obese individuals. Rodent models demonstrate that GC-induced IR is accompanied by compensatory beta-cell hyperplasia. GC excess with high-fat diet leads to fasting hyperglycaemia and suppressed glucose-stimulated insulin secretion (GSIS) despite increased beta cell mass. The majority of in vitro studies confirm an inhibitory GC effect on insulin secretion. The mechanism remains ambiguous but might involve its direct influence upon expression of molecules essential for glucose sensing and metabolism, enhanced glucose cycling, down-regulated insulin gene transcription, hampered insulin exocytosis, amplified alpha-adrenergic signalling, and/or increased beta-cell apoptosis. There are also reports that suggest increased GSIS after beta cell exposure to GCs in vitro. Transgenic mice with enhanced corticosterone regeneration within their beta cells present augmented secretory capacity of their islets. To summarise, GCs exert a significant role in carbohydrate balance through various mechanisms, including direct impact on beta cell function. Observed discrepancies may arise from differences in study design. A thorough understanding of GC action will provide important clinical clues for disorders of glucose homeostasis. (Endokrynol Pol 2017; 68 (5): 568-573)
Introduction
Glucocorticoids (GCs) are 21-carbon steroid hormones synthesised in the fascicular zone of the adrenal cortex. They are indispensable for survival and exert multiple functions in the organism, affecting its growth, reproduction, immune responses, mood, and stress reactions. The strong immunosuppressive and anti-inflammatory properties of GCs led to their widespread use in a number of diseases, including allergic, autoimmune, and haematological conditions, where their dosage usually exceeds the requirements in healthy persons. Moreover, GCs seriously influence carbohydrate, lipid, and protein metabolism [1] . During periods of fasting they enable maintenance of physiological blood glucose levels by decreasing glucose uptake and utilisation in muscle and by stimulating hepatic glucose production (gluconeogenesis and glycogenolysis) [2] . However, GC excess -caused either by pituitary tumours, ectopic ACTH secretion, adrenal tumours, or of exogenous origin -leads to several adverse effects, comprising visceral obesity, impaired glucose homeostasis, dyslipidaemia, and hypertension [3] . Increased serum cortisol levels enhance hepatic glucose output by induction of the gluconeogenesis enzymes: glucose-6-phosphatase, fructose-1,6-bisphosphatase, and phosphoenolpyruvate carboxykinase (PEPCK) [4] . Additionally, GCs stimulate proteolysis in skeletal muscle and lipolysis in adipose tissue, which raises circulating amino acids and glycerol level, i.e. provides more substrates for gluconeogenesis [5, 6] . Moreover, GCs potentiate metabolic effects of other hormones: catecholamines, glucagon, and growth hormone. Thereby, they are known to counteract insulin, although recent data suggest that at a fed state, GCs and insulin might act synergistically to promote the lipid storage [7, 8] . Expansion of the visceral fat in Cushing's syndrome indicates that the GC effect on adipose tissue might be depot-dependent (reviewed in [9] ).
With regard to the carbohydrate metabolism, GCs are best known to contribute to insulin resistance (IR) in the liver and peripheral tissues. In skeletal muscle and adipose tissue, they decrease insulin sensitivity mainly by the post-receptor effects of the insulin signalling. The translocation of the glucose transporter GLUT4 to the cell surface is hence reduced, which in turn leads to decreased glucose uptake [10, 11] . Through their lipolytic effect, GCs increase circulating free fatty acids, which 
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additionally impair insulin sensitivity of the liver and skeletal muscle [12] . Moreover, GCs display an antagonistic action on insulin-stimulated glycogen synthase kinase-3 phosphorylation, thereby lowering glycogen synthesis in skeletal muscle and further contributing to insulin resistance [13] . Impaired insulin responsiveness in peripheral tissues augments insulin demand and challenges its synthesis in pancreatic islets. Chronic administration of exogenous GCs increases fasting and stimulated plasma insulin levels, which reflects a compensatory response of beta cells to decreased insulin sensitivity in peripheries [14, 15] . Therefore, GCs are a well-established risk factor for insulin resistance, leading to impairment of glucose tolerance and subsequent development of diabetes. Finally, recent data suggest that GC may also affect insulin secretion via attenuated incretin effect. Whether this is due to reduced synthesis of the glucagon-like peptide 1 (GLP1) or its impaired action remains a matter of debate and an area for further research [16, 17] .
Unexpectedly, despite the long recognised diabetogenic action of GCs, their direct impact on beta cell function is still not fully defined. Cytoplasmic glucocorticoid receptor (GR), which acts as a ligand--activated transcription factor, is expressed in the pancreas, including beta cells [18, 19] . Upon hormone binding GR is dissociated from heat shock proteins and translocated to the nucleus, where it participates in transactivation or transrepression of the GC target genes. Studies evaluating beta cell responsiveness conditioned by GCs reveal inconsistent results. Most, but not all, in vitro studies indicate an inhibitory GC effect on insulin secretion, whereas the results of in vivo analyses are often confounded by concomitant development of peripheral insulin resistance, and adaptive hyperinsulinaemia [20] . This review aims to present the current understanding of the role of GCs in insulin secretory beta cell function.
Glucocorticoid effects evaluated in vivo
Humans suffering from Cushing's syndrome display impaired glucose tolerance with biochemical indices of decreased insulin sensitivity, detectable already at a subclinical stage of the disease [5, 21-25]. Over 30% of these patients eventually develop diabetes [26] . Increased fasting and postprandial plasma glucose levels reflect the metabolic action of GCs upon the liver and peripheral tissues. Circulating insulin levels are usually elevated; however, compared to obese subjects, patients with Cushing's syndrome present lower insulin output in response to glucose load [22, 23, 27] . This "relative hypoinsulinaemia" was also demonstrated in a study of the effect of two-week exposure to prednisolone, which impaired different aspects of beta cell function evaluated in standardised meal tests [28] . Individuals exposed to chronic exogenous GC excess manifest similar alterations of glucose homeostasis, which may ultimately lead to diabetes [29, 30] . However, even short--term GC treatment (ranging from an overnight infusion up to a six-day course) of healthy volunteers revealed impaired glucose disposal and elevated fasting serum insulin [31] [32] [33] . Individuals with prior deterioration of the beta cell function, so-called "low-insulin responders", are particularly susceptible to further impairment of their glucose tolerance upon GC treatment [34, 35] . Nonetheless, the mechanism of GC diabetogenic action in vivo predominantly involves insulin resistance rather than decreased beta cell mass and capacity for insulin production [36] . Consistent with this, withdrawal of GC substitution in patients with adrenocortical failure improved their insulin sensitivity in terms of enhanced glucose oxidation and reduced endogenous glucose production, with no increase in the insulin output [37] . On the contrary, at high doses (100 mg hydrocortisone, 60 mg prednisone, or 6 mg dexamethasone [DEX] daily) GCs have been shown to decrease insulin secretion in healthy volunteers [38] [39] [40] . However, these observations may reflect beta cell failure due to functional exhaustion or glucotoxicity and not a direct beta cell inhibitory effect [41] .
Animal models enable combined functional in vivo investigation with subsequent morphological assessment of GC effects upon pancreatic islets. Healthy adult rats exposed to a DEX course (5 and 24 days) presented dose-dependent peripheral insulin resistance and hyperglycaemia, with compensatory beta cell proliferation, resulting in increased fractional volume of the endocrine pancreas [42, 43] . By as early as one day, GC treatment resulted in higher fasting and fed circulating insulin levels, although features of impaired glucose tolerance were developing in a time-dependent manner to become evident after five days of DEX administration, together with a marked beta cell hyperplasia [44] . Corticosterone implants in combination with two weeks of high-fat diet led to fasting hyperglycaemia despite increased beta cell mass in young Sprague-Dawley rats, due to combined effect of insulin resistance, hyperglucagonaemia, and impaired beta cell responsiveness to glucose load [45] . High dose of intraperitoneal hydrocortisone was shown to suppress the glucose-stimulated insulin secretion (GSIS) in mice following an intravenous glucose challenge [46] . Forced GC signalling in mature murine beta cells overexpressing GR resulted in lowered GSIS and, consequently, impaired glucose tolerance despite a normal beta cell mass [47, 48] . Prolonged enhancement of the GCs signalling in pancreatic beta cells may aggravate with age and lead to secondary diabetes [49] .
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Inhibitory glucocorticoid effect on insulin secretion in vitro
Considering possible confounding peripheral factors, which affect the analysis of GC impact on pancreas in humans and rodents, in vitro studies can provide better insight into the direct regulatory GC effect on beta cells. However, such investigations have also produced conflicting results, probably because of various study designs, GC preparations used, dosages, and time of exposure, as well as different characteristics of the studied cells. The majority of studies indicate an inhibitory GC effect on insulin secretion in vitro [50] [51] [52] [53] [54] [55] [56] . The effect is dosedependent and abolished by addition of GR antagonist RU486 to the cell culture [47, [56] [57] [58] [59] [60] . GCs reduce both phases of insulin secretion, although the first phase can be particularly affected [47, [56] [57] [58] 61] . On the contrary, GCs do not seem to alter basal insulin secretion in vitro [52, 56] . Some studies indicate a rapid GC inhibitory effect [50, 51] , whereas others demonstrate a delayed onset response [52, 54, 56] . Additionally, prior exposure to DEX attenuates beta cell reaction to other insulin secretagogues, such as potassium, arginine, tolbutamide, and 12-O-tetradeacanoyl phorbol-13-actetate (TPA) [50, 56, 59] . In contrast, isolated islets from the DEX-pretreated rats displayed increased GSIS -perhaps reflecting a rapid compensatory adaptation to insulin resistance, while primary islet cultures from the same strain without prior GCs exposure presented attenuated insulin response to glucose when DEX was added to the culture medium [44] .
The exact mechanisms of the inhibitory GC action on insulin secretion remain ambiguous. Given the regulatory role of GCs in glucose metabolism pathways, one might expect a direct effect on expression of molecules essential for glucose sensing and intracellular metabolism. There is some evidence of enhanced degradation of the glucose transporter GLUT2 and decreased glucokinase expression in DEX-treated beta cell cultures [55, 62] . However, more recent data indicate that both in DEX-treated and control islets mRNA and protein content for GLUT2, glucokinase and pyruvate kinase remain unaltered, and there is no difference in glucose oxidation rate and NADPH rise [56, 59, 63] . This implies that major defects at the level of the beta cell glucose transport and metabolism are unlikely to be the reason for altered GSIS in the presence of GCs in vitro.
Another metabolic concept was that GCs might increase glucose cycling. Normally, a glucose-induced rise in intracellular ATP enables the closure of the ATP-dependent K + channels, which results in depolarisation of the plasma membrane and opening of the voltagedependent Ca 2+ channels, leading to the influx of calcium and efficient insulin exocytosis [64] . Glucose cycling is the simultaneous phosphorylation of glucose to glucose--6-phosphate and its dephosphorylation back to glucose, resulting in ineffective ATP consumption [65] . Enhanced hepatic glucose cycling was demonstrated in vivo in patients with Cushing's syndrome [24] . Normal pancreatic islets display a negligible rate of this futile process because the glucose dephosphorylation rate is very low [66, 67] . However, glucose cycling was considerably elevated in islets from diabetic and obese rodents, and this process was enhanced under the GC influence, through an increase in islet glucose-6-phosphatase activity [53, 66, 68] .
On the other hand, decreased insulin secretion might simply result from impaired insulin synthesis. Indeed, a negative glucocorticoid response element was identified on insulin promoter [69] . Accordingly, DEX exerts a negative regulatory effect on insulin mRNA levels when assessed in dispersed primary rat islet cells [70] . However, an opposite DEX action was noticed with regard to the intact islet cell mass, which was ascribed to higher intracellular cAMP content in clustered cells enhancing their secretory responsiveness [70, 71] . Similar to this latter observation, a stimulatory role of DEX on insulin gene transcription in rat pancreatic islets was also reported in the past [72] . In addition, the inhibition of the insulin synthesis cannot account for the reduced insulin release, because by the end of in vitro experiments, the insulin content in DEX-treated cells was higher than that of the control islets [56, 73] . It cannot be excluded that high-dose or long-term exposure eventually supresses the insulin synthesis [58] , although an inhibitory GC influence on insulin exocytosis seems more likely. Impaired insulin secretion may be linked to an insufficient rise in intracellular calcium, which is required for the activation of the protein kinase Calpha (PKCα) and the phospholipase C (PLC) isozymes, involved in exocytosis of preformed insulin granules [51, 61] . This influence could plausibly take place through increased activity of the K(v)1.5 voltage-gated channels and subsequent decrease in peak values of intracellular calcium, leading to a deleterious effect on membrane depolarisation [74] . However, recent analyses reveal only subtle modifications of the intracellular calcium oscillations in GC-exposed rodent pancreatic islets [56] . Slow onset of the inhibitory effect and its subsequent delayed reversal after DEX removal from the culture medium indicate a plausible genomic inhibitory action upon beta cells [56, 75] . Nonetheless, no decline in intracellular components of the PLC/inositol-1,4,5-triphosphate pathway, normally involved in insulin secretion, was detected under the influence of DEX [59, 63] . Hypothetically, GCs could indirectly affect the insulin secretion by an influence on transcription factors or phosphorylating enzymes required for efficient secretory function [63] .
Another plausible mechanism of the GC action upon beta cells involves enhanced alpha2-adrenergic recep-
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tor signalling, which inhibits the insulin secretion [76] . GCs are known for their modulatory role in the sympathetic nervous system. In beta cells, they seem to specifically up-regulate the alpha2-adrenergic receptor expression, as shown in beta cell lines subjected to GCs as well as in RIP1-GR transgenic mice, which specifically overexpress the GR in their beta cells [49, 77] . In the islets from the RIP1-GR mice, a selective antagonist of the alpha2-receptor restores GSIS, but it has no effect on control islets with normal GR expression [49] .
Finally, it was also hypothesised that GCs might affect insulin biosynthesis via enhanced beta cell apoptosis [78, 79] . Detailed studies in the INS-1 cells derived from the rat insulinoma and in C57BL/6 mouse islets cultured in the presence of DEX (0.1 μM) revealed increased apoptosis rates, an effect abrogated by the addition of RU486 [79] . DEX decreases the expression of the anti-apoptotic Bcl-2 protein, and induces cell death through dephosphorylation of pro-apoptotic BAD protein and stimulation of the mitochondrial apoptotic pathway [75, 79] . In contrast, at higher concentrations (up to 10 μM) DEX was able to reduce cytokine-induced apoptosis in the rat INS-1E cells, although it did not restore GSIS in the presence of inflammatory cytokines [80] . Molecular pathways of the GC-induced apoptosis are still under investigation. GCs may operate through transactivation of genes controlling cellular redox balance and endoplasmic reticulum stress [81, 82] . However, apoptotic changes do not seem to be a major mechanism of impaired beta cell function under the influence of GCs.
Stimulatory glucocorticoid effect on insulin secretion in vitro
Despite prevalent data suggestive of inhibitory GC action on beta cell function, there are some reports that indicate no effect or even an increase in GSIS after GC exposure in vitro [83] [84] [85] . Beta cells from adult rats treated with highdose DEX prior to the islet collection also displayed increased GSIS, whereas pancreatic tissue from the adrenalectomised rats secreted less insulin in response to perfused glucose [15, 63, 84, 86] . Compared to the control samples, islets isolated from DEX-treated rats that exhibited insulin hypersecretion in response to glucose, revealed enhanced mitochondrial function, augmented Ca 2+ signalling, and increased PLC/PKC activity [63] . Increased peak GSIS was also reported in perfused ex vivo islets from DEX-treated rats maintained on a high-fat diet, and this observation contrasted with in vivo studies in the same animals, which displayed fasting hyperinsulinaemia but a blunted early phase reaction to intravenous glucose load compared to the rats on high-fat diet without DEX [87] . Therefore, in the intact organism, the adaptive GC-induced increase in insulin secretion might be modulated by additional metabolic or hormonal factors. Short-term in vitro corticosterone exposure of pancreatic islets derived from lean C57BL/6 mice did not affect basal insulin secretion but enhanced both GSIS phases, with marked elevation of the early insulin release persisting even after prolonged GCs treatment [88] . Significant differences in expression of several genes involved in signal transduction, cellular stress response, and nucleotide and lipid metabolism were also described in this latter study.
Discrepant observations of the GC influence on beta cell function may arise from different organisms studied, various doses of GCs applied, and different times of exposure. They also support the notion that there might be a certain optimal GC level required for adequate beta cell function. Heterozygous transgenic mice displaying a moderate increase in activity of type 1 11beta-hydroxysteroid dehydrogenase and enhanced local regeneration of active corticosterone within their beta cells, even when maintained on high-fat diet, displayed improved response to intravenous glucose load compared to controls lacking the transgene [89] . Moreover, their islets featured augmented secretory capacity and an up-regulation of genes connected with differentiation, secretory pathways, and cellular stress management [89] . This model of increased exposure to GCs seems closer to the physiology, as indicated by lack of suppression of proinflammatory genes, which was otherwise reported in islets exposed to high levels of exogenous corticosterone [88] .
Summary
GCs exert a significant role in carbohydrate balance through various mechanisms, including direct impact on beta cell secretory function. Thorough understanding of these actions as well as better insights into early origins of the GC-induced metabolic disorders may provide important clinical clues for the study of diabetes. This would be especially valuable in the context of prevention and new treatment measures, but also with regard to future developments in beta cell preservation and transplantation procedures. 
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Streszczenie
Glikokortykosteroidy (GKS) odgrywają istotną rolę w metabolizmie węglowodanów. Działają przeciwstawnie do insuliny poprzez zmniejszanie obwodowego wychwytu glukozy i stymulowanie glukoneogenezy wątrobowej, ale ich najbardziej znane działanie dotyczy indukcji insulinooporności (IR). Ponadto GKS mogą osłabiać efekt inkretynowy. Wpływ GKS na komórki beta pozostaje nie w pełni wyjaśniony. Celem niniejszej pracy jest prezentacja aktualnego stanu wiedzy na ten temat. Osoby eksponowane na nadmiar GKS wykazują IR, upośledzoną tolerancję glukozy, a ostatecznie rozwój cukrzycy. Pomimo że stęże-nia insuliny są u nich podwyższone, prezentują mniejsze wydzielanie insuliny w odpowiedzi na glukozę w porównaniu z osobami z otyłością. Wyniki badań prowadzonych na modelach zwierzęcych wskazują, że indukowanej glikokortykosteroidami IR towarzyszy kompensacyjna hiperplazja komórek beta. Nadmiar GKS w połączeniu z dietą bogatotłuszczową prowadzi do hiperglikemii na czczo oraz supresji stymulowanej glukozą sekrecji insuliny (GSIS, glucose stimulated insulin secretion) pomimo zwiększenia masy komórek beta. Wyniki większości badań in vitro potwierdzają hamujący wpływ GKS na wydzielanie insuliny. Mechanizm pozostaje jednak niejasny i może obejmować bezpośredni wpływ GKS na ekspresję cząsteczek zaangażowanych w wykrywanie krążącej glukozy oraz jej metabolizm wewnątrzkomórkowy, wzmożone tak zwanym glucose cycling, zmniejszenie transkrypcji genu insuliny, zaburzenie jej egzocytozy, nasilenie przekaźnictwa alfa-adrenergicznego i/lub zwiększoną apoptozę komórek beta. Istnieją również doniesienia sugerujące wzrost GSIS po ekspozycji komórek beta na GKS in vitro. Transgeniczne myszy z nasiloną regeneracją kortykosteronu w komórkach beta prezentują zwiększoną wydolność wydzielniczą wysp trzustkowych. Podsumowując, GKS oddziałują na równowagę węglowodanową poprzez różnorodne mechanizmy, w tym bezpośredni wpływ na czynność komórek beta. Stwierdzane rozbieżności mogą być wynikiem odmiennej metodyki badawczej. Kompletne zrozumienie działania GKS dostarczy ważnych wskazówek klinicznych w zakresie zaburzeń homeostazy węglowodanowej. 
Wstęp
Glikokortykosteroidy (GKS) to 21-węglowe hormony steroidowe syntetyzowane w warstwie pasmowatej kory nadnerczy. Są konieczne dla przeżycia i spełnia-ją różnorodne funkcje w ustroju, wpływając na jego wzrastanie, reprodukcję, odpowiedź immunologiczną, nastrój oraz reakcje stresowe. Właściwości immunosupresyjne i przeciwzapalne GKS doprowadziły do ich szerokiego zastosowania w wielu schorzeniach, między innymi w chorobach alergicznych, autoimmunologicznych i hematologicznych, zazwyczaj w dawkach daleko przewyższających zapotrzebowanie u osób zdrowych. Glikokortykosteroidy znacząco wpływają na metabolizm węglowodanów, lipidów i białek [1] . W okresach postu umożliwiają utrzymanie fizjologicznych stężeń glukozy we krwi poprzez zmniejszenie jej wychwytu i wykorzystania w mięśniach oraz przez stymulację wątrobowej produkcji glukozy (glukoneogeneza i glikogenoliza) [2] . Nadmiar GKS -spowodowany guzami przysadki, ektopowym wydzielaniem hormonu adrenokortykotropowego (ACTH, adrenocorticotropic hormone) guzami nadnerczy, albo pochodzenia egzogennego -prowadzi do licznych efektów niepożądanych, obejmujących otyłość trzewną, upośledzoną homeostazę glukozy, dyslipidemię oraz nadciśnienie tętnicze [3] . Podwyższone stęże-nia kortyzolu w surowicy nasilają uwalnianie glukozy z wątroby poprzez indukcję enzymów glukoneogenezy: glukozo-6-fosfatazy, fruktozo- 
